Identification of Potential Prognostic Markers for Knee Osteoarthritis by Serum Proteomic Analysis. Issue 8 (January 2013)

• Record Type: Journal Article
• Authors: Takinami, Yoshihiko; Yoshimatsu, Shinya; Uchiumi, Takaoki; Toyosaki-Maeda, Tomoko; Morita, Atsushi; Ishihara, Takeshi; Yamane, Shoji; Fukuda, Isao; Okamoto, Hiroyuki; Numata, Yoshito; Fukui, Naoshi
• Is Part Of: Biomarker insights. Volume 2013:Issue 8(2013)
• Publication Date: 2013-01
• Subjects: osteoarthritis -- biomarker -- proteomics -- surface-enhanced laser desorption/ionization (SELDI); Biochemical markers -- Periodicals; 572.43
• DOI: 10.4137/BMI.S11966
• Languages: English
• ISSNs: 1177-2719

Abstract

Background: As osteoarthritis (OA) is a highly heterogeneous disease in terms of progression, establishment of prognostic biomarkers would be highly beneficial for treatment. The present study was performed to identify novel biomarkers capable of predicting the progression of knee OA. Methods: A total of 69 plasma samples (OA patients undergoing radiographic progression, n = 25; nonprogression, n = 33; healthy donors, n = 11) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), and ion peaks of interest were identified by liquid chromatography and matrix-assisted laser desorption/ionization (MALDI)-TOF MS. The identities of these proteins were further validated by immunoprecipitation combined with SELDI-TOF MS analysis. Results: SELDI-TOF MS analysis indicated that the intensities of 3 ion peaks differed significantly between progressors and nonprogressors. Subsequent analyses indicated that these peaks corresponded to apolipoprotein C-I, C-III, and an N-terminal truncated form of transthyretin, respectively. The identities of these proteins were confirmed by the loss of ion peaks in SELDI-TOF MS spectra by immunoprecipitation using specific antibodies for the respective proteins. Conclusions: Three potential biomarkers were identified whose serum levels differed significantly between OA progressors and nonprogressors. These biomarkers are expected to be prognostic biomarkers for knee OA and to facilitate the development of novel disease-modifying treatments for OA.